A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension

M
Marcia Felker, MD

Primary Investigator

Overview

This study is being done to see if Ataluren will slow the progression of DMD in boys with DMD who have specific mutations.

Description

The main goals of this study are to obtain additional information on whether the actions of ataluren can slow disease progression as assessed by tests for walking, lower-limb muscle function, upper-limb muscle function for children 7 years of age and older, muscle strength for children under 7 years of age, magnetic resonance imaging (MRI) only at participating sites, and health-related quality of life (HRQL) in males with DMD, and provide additional information on the safety of ataluren over 144 weeks.

 

Participants will be compensated for their participation.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Nonsense Mutation Duchenne Muscular Dystrophy
  • Age: Between 7 Years - 100 Years
  • Gender: Male

Inclusion Criteria

Diagnosed with nonsense mutation DMD confirmed by medical history and genotyping

Able to stand, walk, climb, and descend stairs

Taking corticosteroid treatment for DMD for at least 12 months

Updated on 09 Mar 2024. Study ID: 1809416902

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center